Advertisement Animascope Announces its Merging with Spectroscan - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More


Preclinical Imaging Services

More info about Animascope

Animascope Announces its Merging with Spectroscan

Spectroscan brings the licence of their patent on the CRS for « health applications » in exclusivity, for 49% of Animascope. All the Spectroscan’s employees join Animascope, while Spectroscan continues to adress its historial market on Non Destructive Analysis.

SPECTROSCAN has developped a proprietary method based on Computational Tomography together with a dedicated machine named Contrôle Radiosynthétique (CRS) protected by an european patent with a lot of application in medical imaging, safety and industrial controls on line.